Source comparison
Melanotan-1 vs Melanotan-2: Half-Life Comparison
Plasma Half-Life 30–45 minutes 33–40 minutes Virtually identical elimination kinetics. Both are cleared rapidly via renal filtration and hepatic proteolysis Receptor Selectivity MC1R-selective (>1000× selectivity vs MC3R/MC4R) Non-selective (activates MC1R, MC
This comparison does not assign a generated winner or score.
- Plasma Half-Life
- 30–45 minutes
- 33–40 minutes
- Virtually identical elimination kinetics. Both are cleared rapidly via renal filtration and hepatic proteolysis
- Receptor Selectivity
- MC1R-selective (>1000× selectivity vs MC3R/MC4R)
- Non-selective (activates MC1R, MC3R, MC4R, MC5R)
- Melanotan-1's selectivity eliminates sexual side effects and nausea common with MT-2; this is the critical clinical differentiator
- Melanogenic Duration
- 72–96 hours per dose
- 48–72 hours per dose
- Melanotan-1 produces longer-lasting melanogenesis despite identical half-life. Likely due to sustained MC1R occupancy or slower receptor internalization
- FDA Approval Status
- Approved (Scenesse for EPP, EU/US)
- Not approved (research use only)
- Melanotan-1 has completed Phase III trials and regulatory review; melanotan-2 lacks any formal clinical development pathway
- Typical Dosing Interval
- Every 48–72 hours (induction) or 60-day implant
- Daily or alternate-day (research protocols)
- MT-1's longer effect duration allows less frequent administration despite similar pharmacokinetics
- Primary Clearance Route
- Renal excretion (>80%)
- Renal excretion (~70–80%)
- Both require dose adjustment in renal impairment; creatinine clearance <30 mL/min contraindicates use